Share Twitter LinkedIn Facebook Email Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with high-risk disease treated with ibrutinib.
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
BTK Inhibitor Use and Social Determinants in CLL / SLL [ASH 2023] Chronic Lymphocytic Leukemia 2 Mins Read
Elevate-TN: Treatment-Naive CLL Treated with Acalabrutinib – ASH Chronic Lymphocytic Leukemia 2 Mins Read